ASCO 2012
Interviews and expert commentary from ASCO 2012 — study authors and key opinion leaders discuss the findings and their clinical implications.
Audio Journal of Oncology
ASCO 2012 ANNUAL MEETING: Outgoing ASCO President Michael Link Comments On Key New Clinical Research Findings
CHICAGO—The outgoing president of ASCO, Dr Michael Link from Stanford University School of Medicine in California, answers questions from Peter Goodwin about the progress achieved in cancer clinical s
11 June 2012
0:00
Audio Journal of Oncology
ASCO 2012 ANNUAL MEETING: Targeted Drug Afatinib Delays Progression of Advanced Lung Cancers, Particularly Those With Specific Genetic Mutations
CHICAGO—Findings from a Phase III trial show that initial single-agent therapy with a new oral drug called afatinib prolongs progression- free survival in patients with advanced lung adenocarcinomas t
11 June 2012
0:00
Audio Journal of Oncology
ASCO 2012 ANNUAL MEETING: Resolving Long Debate, Study Finds Intermittent Hormonal Therapy Less Effective than Continuous Therapy in Certain Men With Advanced Prostate Cancer
CHICAGO—At the Plenary Session of ASCO Maha Hussain MD, FACP of the University of Michigan in Ann Arbor presented results from a long-term, multicenter Phase III international clinical trial comparing
11 June 2012
0:00